INDP (Indaptus Therapeutics) Short-Term Debt to Capital

Indaptus Therapeutics (INDP) is implementing AI and robotics to accelerate the selection of immuno-oncology compounds, while the asset's market value dynamics are currently at 0.00. The business relies on a platform with bacterial components that creates a strong systemic response against neoplasms. The company's capitalization is independent of the economy and is determined exclusively by the results of trials for new methods of stimulating immune defense.

The long-term sustainability of the issuer is determined by the ability to balance short-term liabilities against equity, where the ratio of loans maturing within one year to equity reflects the risk of cash flow gaps versus expansion potential. For Indaptus Therapeutics (INDP), which is under strict FDA oversight during Phase 1 clinical trials and currently generates no revenue, this indicator confirms the preservation of liquidity necessary to sustain the development of bacterial vectors.